Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-16 | 2024-06 | -9.91 | -19.28 | -9.37 | -94.55% |
2024-05-13 | 2024-03 | -16.61 | -5.75 | 10.86 | 65.38% |
2024-04-01 | 2023-12 | -49.84 | -27.48 | 22.36 | 44.86% |
2023-11-09 | 2023-09 | -47.6 | -58.47 | -10.87 | -22.84% |
2023-08-10 | 2023-06 | -88.82 | -85.62 | 3.2 | 3.60% |
2023-05-08 | 2023-03 | -79.87 | -103.83 | -23.96 | -30.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-07-31 | Alliance Global Partners | Upgrade | Buy | Buy |
2023-06-01 | Alliance Global Partners | Upgrade | Buy | Buy |
2021-08-30 | Alliance Global Partners | Upgrade | Buy | Buy |
2021-08-10 | Alliance Global Partners | Upgrade | Buy | Buy |
2021-02-24 | Alliance Global Partners | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2020-08-12 | BAGGER RICHARD H | Director | 10.00K | Purchase |
2020-08-19 | BELL MARGARET SMITH | Director | 5.39K | Purchase |
2021-05-24 | GOODMAN DANIEL WINTNER M.D. | Director | 5.00K | Purchase |
2022-06-28 | LEDERMAN SETH | Chief Executive Officer | 0.00 | Purchase |
2018-06-24 | MARIO ERNEST B | Director | 0.00 | Purchase |
2018-06-13 | MORRIS JESSICA EDGAR | Chief Operating Officer | 1.64K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 398.75K | 630.03K | 2.24% |
2023-06-29 | Renaissance Technologies, LLC | 211.42K | 334.05K | 1.19% |
2023-06-29 | Geode Capital Management, LLC | 85.37K | 134.88K | 0.48% |
2023-06-29 | Acadian Asset Management. LLC | 68.74K | 108.61K | 0.39% |
2023-06-29 | Blackrock Inc. | 48.34K | 76.38K | 0.27% |
2023-06-29 | Raymond James & Associates, Inc. | 44.36K | 70.10K | 0.25% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 297.30K | 469.74K | 1.67% |
2023-06-29 | Vanguard Extended Market Index Fund | 100.84K | 159.33K | 0.57% |
2023-05-30 | Fidelity Extended Market Index Fund | 49.98K | 89.47K | 0.28% |
2023-05-30 | Fidelity Total Market Index Fund | 13.51K | 24.18K | 0.08% |
2023-05-30 | Fidelity Series Total Market Index Fund | 9.14K | 16.35K | 0.05% |
2023-08-30 | iShares Core S&P Total U.S. Stock Market ETF | 6.31K | 6.10K | 0.04% |
Split | Date |
---|---|
1 : 32 | 2024-06-10 |
4 : 25 | 2023-05-10 |
1 : 32 | 2022-05-17 |
1 : 10 | 2019-11-01 |
1 : 10 | 2018-11-28 |
1 : 10 | 2017-03-17 |
-
$TNXP this company is HUGE ! Gold ! $5 soon!
-
-
-
$TNXP OVER $3 by tomorrow !!!!!!
-
$TNXP know what you own this stock is $10
-
TNXP Stock: A Top COVID-19 Vaccine Play
Alex CarlsonJuly 23, 2020
There’s no denying the best sector for investors right now is the COVID-19 vaccine plays. We at Insider Financial have nailed quite a few this year, from Inovio Pharmaceuticals to Moderna to Vaxart and most recently with Heat Biologics. Now we are turning our attention to TNXP stock, a name that we have covered in the past and another Covid-19 vaccine player that has yet to make a huge move like Inovio, Moderna, Vaxart, and Heat Biologics, but soon will.The Importance Of T-Cells
The reason we like TNXP stock so much right now is the new evidence that is coming out regarding immunity to COVID-19. Evidence is emerging that T-cells, which can “remember” past infections and kill pathogens if they reappear, have a big influence on how long patients remain resistant to reinfection by Covid-19. The cells, whose size and complexity dwarf tiny antibodies, also appear to affect how well vaccines work and even the level of immunity in the community required to suppress new waves of disease.
People who recovered from Sars, the disease most closely related to Covid-19, in 2003 still show cellular immunity to that coronavirus 17 years later. T-cells, which circulate in the blood, might protect people who have been infected and recovered from the new coronavirus but have no detectable antibodies shortly thereafter. According to Al Edwards, associate professor at Reading University’s School of Pharmacy:
“T-cells are tasting the virus whereas the antibodies are feeling the virus. T-cells can promote antibody responses and antibody responses can promote a T-cell response. These two systems work together.”
TNXP Stock and Southern Research
TNXP stock is collaborating with Southern Research on a COVID-19 vaccine. The two have just expanded their collaboration focusing specifically on T cell immune responses to SARS-CoV-2 in volunteers who have recovered from the disease or who remain asymptomatic after exposure to COVID-19. Raj Kalkeri, Ph.D., MBA, a senior scientist in Southern Research’s Infectious Disease Research Group, said the study’s findings will shed new light on the role that T cells – a central part of the immune system – may play in the development of a vaccine against the novel coronavirus.
-
$TNXP
Bashing science & medical is total ignorance!!!
If you do not understand what T Cell means!! Go get a book & read if you know how to read you idiots!!!
You do not belong in investment trading.
You belong in Casino in front of Penny machine you idiots!!
Get some real knowledge about investing in Bio pharma stocks!
TNXP board will prove everyone soon!!!
Hold your shares & you will be rewarded soon -
-
-
-
-
Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. That’s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
-
Big wave of money will come tomorrow ; this Stock have many vaccines in development also CoVid 19 with Columbia University help
-
-
-
Taking the lead: Tonix Pharmaceuticals Holding Corp (TNXP)
news.google.com • -
Examining Tonix Pharmaceuticals Holding Corp (TNXP) stock is warranted
news.google.com •